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Angiotensin converting enzyme inhibitor ACEI-induced angioedema of the intestine is a rare occurrence and often unrecognized
complication of ACEI. We present a case of a 45-year-old Hispanic female with angioedema of the small bowel progressing to
facial and oral pharyngeal angioedema. Patients are typically middle-aged females on ACEI therapy who present to the emergency
department with abdominal pain, nausea, vomiting, and diarrhea. This is a diagnosis of exclusion, and physicians must have a
high index of suspicion to make the diagnosis. Symptoms typically resolve within 24–48 hours after ACE inhibitor withdrawal.
Recognizing these signs and symptoms, and discontinuing the medication, can save a patient from unnecessary, costly, and invasive
procedures.

1. Introduction
Angioedema of the face and oral pharynx is a well-recognized
complication of ACE inhibitor therapy. These medications
can also cause angioedema of the bowel and may present
a diagnostic dilemma to the emergency physician. Patients
typically present with a complaint of abdominal pain
with or without vomiting and diarrhea. Workup is usually
nondiagnostic including leukocytosis and nonspecific bowel
wall thickening on CT scan. Therapy consists of withdrawal
of the medication. This is a diagnosis of exclusion, and
physicians must have a high index of suspicion. Making the
diagnosis can prevent patients from exposure to costly and
invasive procedures.

2. Case Report
A 45-year-old Hispanic female presented to the emergency
department with a chief complaint of severe abdominal pain
for the last several days that progressed to severe pain over the
last 24 hours. Approximately one week ago, the patient was
evaluated at another facility for a complaint of abdominal

pain. Lab tests showed an elevated lipase, and the patient
was diagnosed with pancreatitis. She was discharged home
and instructed to follow a clear liquid diet and advance as
tolerated.
The patient’s past medical history was significant for
hypertension, type 2 diabetes, chronic renal failure requiring
dialysis, and the recent diagnosis of pancreatitis. Her medications included enalapril/hydrochlorothiazide, hydralazine,
clonidine, metoprolol, metoclopramide, promethazine, mirtazapine, pantoprazole, insulin NPH/regular 70/30, alprazolam, and zolpidem.
On initial evaluation, the patient was complaining of
several days of sharp, crampy abdominal pain worsening over
the 24 hours prior to arrival. She complained of nausea,
vomiting, and watery diarrhea for the past day. She denied
fever, chills, dizziness, weakness, headache, chest pain, or
shortness of breath. She denied blood in her emesis, stool, or
urine. The remainder of the review of systems was negative.
On initial physical exam, vital signs were significant
for hypertension (175/86) and mild tachycardia (107). The
patient appeared to be in acute distress secondary to pain.
She was alert and oriented, oral pharynx was clear with no
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edema, erythema, or exudates, and neck was supple with
full range of motion. Her lungs were clear to auscultation
bilaterally. Cardiac exam was significant for tachycardia
with a regular rhythm, no murmurs, rubs, or gallops.
The patient’s abdomen was diﬀusely tender and worse in
the mid-epigastric and periumbilical region. She had no
peritoneal signs, and rectal exam was hemoccult negative.
The remainder of her physical exam was unremarkable.
Initial labs were significant for an elevated white blood
cell count of 19.8 K/UL with a left shift, and the rest of
the hemogram was normal. Her metabolic panel revealed a
BUN of 29 mg/dL and creatinine of 5.8 mg/dL (which was
consistent with her baseline). Serum glucose was 182 mg/dL,
amylase slightly elevated at 203 U/L (normal 36–128 U/L),
lipase 43 U/L (normal 10–51 U/L), and liver function tests
were normal.
CT scan of the abdomen and pelvis was limited due to
the lack of IV contrast with no significant findings other than
mild edema of the small bowel, with No pancreatic swelling,
fat stranding, fluid collection, free fluid in the abdomen,
lymphadenopathy, or masses.
The patient was given multiple doses of hydromorphone
during her stay in the emergency department, with only
minimal improvement of her pain. The patient was reevaluated on several occasions with no change in her physical
exam. Shortly after returning from CT, the patient began
complaining of diﬃculty swallowing and mild shortness
of breath. Upon reevaluation at that time, the patient
was found to have diﬀuse swelling of her face, neck, lips,
oral pharynx, and tongue. The patient required emergent
fiberoptic intubation and was admitted to the intensive care
unit. During her hospitalization, C1 esterase inhibitor and
complement levels were all within normal limits.
The patient was diagnosed with ACEI angioedema of the
oral pharynx and small intestine. The ACEI was discontinued
at the time of admission. The swelling improved, and she
was extubated after 48 hours. The patient’s abdominal pain
resolved, and she was discharged home with instructions to
avoid ACEI in the future. At followup visits over the next six
months, the patient’s abdominal pain had not returned (see
Figures 1 and 2).

3. Discussion
After review of the English literature, we were able to find
21 documented cases of ACEI-induced angioedema of the
bowel [1–10]. Patients typically present with unexplained
abdominal pain despite extensive evaluation [1, 2]. The
patient in this case initially presented with abdominal pain
due to angioedema of the bowel. While in the emergency
department, she progressed to angioedema of the face
and oral pharynx, which is a rapid and atypical onset of
angioedema from ACEI.
Pancreatitis, obstruction, mesenteric ischemia, infection,
cholecystitis among other abdominal emergencies, and C1
esterase inhibitor deficiency all need to be considered in the
diﬀerential. Although the CT of the abdomen and pelvis was
done without IV and oral contrast, which is recommended
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Figure 2

to fully appreciate pathology of the pancreas, it did not reveal
any signs of pancreatitis. The patient’s labs and CT scan were
not consistent with a diagnosis of pancreatitis, obstruction,
or acute infection. C1 esterase inhibitor deficiency was ruled
out during her admission. As her facial angioedema resolved,
so did her abdominal pain. The abdominal pain did not
return after discontinuing the ACE inhibitor, leading to this
diagnosis of exclusion. At 6-month followup, the patient
remained free of abdominal pain.
Approximately 30% of all ED visits for angioedema are
from ACEI, while the annual rate of ED visits for ACEIinduced angioedema is 0.7 per 10,000 [11, 12]. Angioedema
is asymmetrical nonpitting edema of the skin or mucus
membrane and a well-documented side eﬀect of ACEI
[13]. ACEI-induced angioedema typically aﬀects the face,
eyelids, lips, tongue, neck, and pharynx, while urticaria or
pruritis is seen only rarely [11, 13–17]. These adverse eﬀects
commonly present within the first 4 weeks after initiation of
therapy and have not shown to be dose related or caused
by one particular ACEI [13–16]. No definitive predisposing
factors have been identified although the current literature
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suggests that patients with a history of either hereditary or
idiopathic angioedema are at an increased risk for ACEIinduced angioedema [13, 15, 16]. Japanese patients have a
lower incidence of angioedema from ACEI while several case
reports have shown that patients of African origin have a
significantly increased relative risk [13, 14, 18, 19].
The mechanism of action by which ACEI causes
angioedema is not fully understood, but it is theorized
to be from a biochemical rather than immunological
reaction [16]. ACE converts angiotensin I to angiotensin
II while also inactivating bradykinin. Increased levels of
bradykinin, along with other mediators, are responsible for
the angioedema reaction [13, 15, 16, 20]. Bradykinin causes
vasodilatation and increased vascular permeability, thereby
leading to angioedema. Some studies suggest that patients
with a deficiency of aminopeptidase-P, another enzyme that
catabolizes bradykinin, are at an increased risk of developing
of angioedema from ACEI [13, 17, 20].
ACE inhibitor-induced angioedema of the intestines is a
diagnosis that should be considered in any patient presenting
with unexplained abdominal pain while on an ACE inhibitor.
The incidence of ACE inhibitor-induced angioedema is low
(0.1%–0.2%) with a small fraction of those representing
angioedema of the bowel [1–4]. However, the exact incidence
is unknown and is likely underdiagnosed [1, 4]. ACE
inhibitor angioedema of the intestine is more common in
females, with an average age of 48 years, suggesting a possible
sex-linked or hormonal etiology [4, 9]. Common symptoms
include abdominal pain, vomiting, diarrhea, and ascites
[3–5]. Symptoms typically present within 24–48 hours of
initiation of an ACE inhibitor, but there are case reports of
facial angioedema 7 years after initiation of therapy [6] and
bowel angioedema 9 months after initiation of therapy [3].
The management of ACEI angioedema should be prompt
and aggressive with careful attention to airway management.
Treatment can range from simple discontinuation of ACEI
therapy to intubation and vasopressors, depending on the
severity of the reaction. Angioedema of the intestine is
reversible with cessation of the medication. Many of the
patients discussed in the literature underwent invasive procedures including endoscopy, intestinal biopsy, exploratory
laparotomy, and bowel resection, before a diagnosis of ACE
inhibitor induced angioedema was made [1, 3, 4, 9]. Swift
recognition is necessary to prevent unwarranted procedures,
surgical intervention, or potentially death. Symptoms typically resolve within 24–48 hours after discontinuing the ACEI
and continue to improve over the next 1 to 2 months [2, 10].

4. Conclusion
ACE inhibitor angioedema is a rare occurrence with intestinal involvement being less common. Unfortunately there is
no specific test that can be used to diagnose the condition.
Failure to make the correct diagnosis can place patients at
increased risk of adverse outcomes due to invasive testing and
procedures. While there does appear to be a greater risk of
occurrence early in therapy, angioedema can present at any
time and thus when treating any patient with abdominal pain
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use of ACEI therapy should be considered in the diﬀerential
diagnosis.
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